Clinical Trial Update: Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating oral galactose for the FSGS permeability factor has been terminated. The study, sponsored by Northwell Health, ends without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Galactose (oral) (galactose)

Snippet

Sponsor: Northwell Health | Conditions: Focal Segmental Glomerulosclerosis | Phase 1 | Status: TERMINATED